Start of main content

Personalized Precision Oncology: current status and future perspectives

Life and Matter Sciences Seminar Thursday, March,21st - 22nd, 2019 9:30 hours Madrid

General information:

Venue: Fundación Ramón Areces - salón de actos. Calle Vitruvio, 5. 28006. Madrid.

Limited capacity. Free registration.

Organized by:

Fundación Ramón Areces

Coordinator/s:

Juan Carlos LacalHospital Universitario de Fuenlabrada, Madrid

Manuel HidalgoBeth Israel Deaconess Medical Center, Harvard Medical School, Boston

Multimedia

Eduardo Díaz Rubio's full lecture

Multimedia

Carlos Arteaga's full lecture

Multimedia

Rafael Rosell's full lecture

Multimedia

Patrick Tan's full lecture

Multimedia

Manuel Hidalgo's full lecture

Multimedia

Florian Markowetz's full lecture

Multimedia

Santiago Ramón y Cajal's full lecture

Multimedia

Pier Paolo Pandolfi's full lecture

Multimedia

Enzo Medico's full lecture

Multimedia

Eric Aboagye's full lecture

Multimedia

Felipe Calvo's full lecture

Multimedia

José Martínez Olmos's full lecture

Multimedia

Fernando Bandrés's full lecture

Multimedia

Paul Workman's full lecture

See more media from this activity

Description
Programme

T hroughout the last 50 years huge advance in the knowledge of the molecular basis of the onset and progression of cancer has been achieved. This improved understanding has allowed a more precise classification of the more than 200 diseases grouped under this common designation, showing the existence of diverse subtypes in the vast majority of cases. As a result, the clinical management of patients has been modulated with spectacular results in some cases, moving from universal therapies (one fits all) based on trials of large cohorts of patients based on their histological classification. However, many pathologies remain elusive to the implemented successful therapies, a clear indication that despite the progress made there are still many enigmas to be solved leaving room for improvement based on new anti-tumour strategies. Personalized precision oncology emerges from the ever increasingly accurate and effective development of diagnostic technologies. With a better identification of the alterations that define each particular tumour, rather than their histological origin, each tumour turns into an individual enemy that allows to design personalized treatments with greater precision against their weakest flanks. This Symposium will update some strategies that are either successfully used in personalised precision oncology treatments or have the potential to become therapeutic strategies in the immediate future. Personalized medicine has raised some concerns that deserve attention at clinical, ethical, legal and economical levels that will be discussed.

Thursday, 21

9:30 h.

Welcome

Manuel Hidalgo
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston

Juan Carlos Lacal
Hospital Universitario de Fuenlabrada, Madrid

Mariano Barbacid
Consejo Científico Fundación Ramón Areces

9:45 h.

Keynote Lecture: The History of Treatment Strategies in Oncology

Eduardo Díaz Rubio
Hospital Clínico San Carlos, Madrid
Vicepresident, Real Academia Nacional de Medicina

SESSION 1: New Targets in Cancer Drug Discovery: Defining Tools for Precision Oncology

Chairpersons:
Carlos Arteaga
UT Southwestern Simmons Cancer Center
Patrick Tan
Duke-NUS Medical School, Singapore

10:50 h.

Actionable Genomic Alterations in Breast Cancer

Carlos Arteaga
UT Southwestern Simmons Cancer Center

11:30 h.

New targets in lung cancer

Rafael Rosell
Instituto Oncológico Dr. Rosell, Hospital Universitario Quirón-Dexeus, Barcelona

12:10 h.

Break

12:40 h.

Drugging the metabolism of cancer cells

Juan Carlos Lacal
Hospital Universitario de Fuenlabrada, Madrid

13:20 h.

Epigenomic Alterations in Asian-Endemic Cancers

Patrick Tan
Duke-NUS Medical School, Singapore

14:00 h.

Break

SESSION 2: Experimental Models for Implementing Precision Oncology

Chairpersons:
Manuel Hidalgo
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston
Pier Paolo Pandolfi
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston

16:00 h.

New therapeutic approaches in pancreatic cancer

Manuel Hidalgo
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston

16:40 h.

Inferring active mutational processes shaping copy number of cancer genomes

Florian Markowetz
University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge

17:20 h.

Intratumor Heterogeneity. How we envision it

Santiago Ramón y Cajal
Hospital Universitario Vall d’Hebron, Barcelona

18:00 h.

Break

18:20 h.

Reactivation of tumor suppressors for cancer prevention and therapy

Pier Paolo Pandolfi
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston

19:00 h.

Oncogenomics and patient-derived preclinical models for colorectal cancer precision medicine

Enzo Medico
University of Torino, FPO-IRCCS, Turin

Friday, 22

SESSION 3: Clinical Approaches to Develop Personalized Precision Oncology

Chairpersons:
Ignacio Melero
Clínica Universidad de Navarra, Center for Applied Medical Research (CIMA), Pamplona.
Felipe Calvo
Clínica Universidad de Navarra, Madrid.

9:30 h.